Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.41 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 known ✓ | P23458 | 2/20 | 0.39 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.35 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.35 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.35 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.35 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.35 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.34 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16899760 | 1.00 | BMPR1A (0.41) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| Hydrochloric Acid SCHEMBL16899730 | 1.00 | BMPR1A (0.41) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| SCHEMBL16899731 | 0.98 | BMPR1A (0.42) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| SCHEMBL16899735 | 0.98 | BMPR1A (0.42) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| SCHEMBL16899815 | 0.98 | BMPR1A (0.42) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| SCHEMBL20519747 | 0.89 | CHRNB2 (0.40) | HTR2BMETKDM5AHTR6HTR2A | |
| Hydrochloric Acid SCHEMBL1427789 | 0.83 | KDM5A (0.36) | JAK1KDM5A | |
| Tert-Butyl Formate SCHEMBL27825726 | 0.83 | JAK2 (0.36) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| Tert-Butyl Formate SCHEMBL27825727 | 0.83 | JAK2 (0.36) | BMPR1AACVRL1ACVR1JAK2JAK1 | |
| SCHEMBL2600281 | 0.83 | JAK2 (0.42) | BMPR1AACVRL1ACVR1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-113272297-B | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11890275-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 2024-02-06 | — | — | US | disclosed |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| CN-113272297-A | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11020380-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3092225-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | Merck Patent GmbH (DE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | HRH4, HRH3, HRH2 | ACVR1 1242/4885JAK2 792/4885JAK1 1708/4885 |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | ACVR1 3956/4885JAK2 35/4885JAK1 56/4885 |
| US-11020380-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-20240293381-A1 | Therapeutic Compounds | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | ACVR1 1328/4885JAK2 594/4885JAK1 1462/4885 |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | IRAK2, IRAK3, IRAK1 | ACVR1 3814/4885JAK2 62/4885JAK1 57/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | ACVR1 1328/4885JAK2 594/4885JAK1 1462/4885 |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
| US-11890275-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | ACVR1 3736/4885JAK2 396/4885JAK1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.